Literature DB >> 24269732

Inhibition of storage pathology in prenatal CLN5-deficient sheep neural cultures by lentiviral gene therapy.

Stephanie M Hughes1, Katie M Hope2, Janet Boyu Xu3, Nadia L Mitchell4, David N Palmer5.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs, Batten disease) are inherited neurodegenerative lysosomal storage diseases caused by mutations in several different genes. Mutations in CLN5 cause a variant late-infantile human disease and some cases of juvenile and adult clinical disease. NCLs also occur in animals, and a flock of New Zealand Borderdale sheep with a CLN5 splice-site mutation has been developed for model studies. Dissociated mixed neural cells from CLN5-deficient foetal sheep brains contained no obvious storage bodies at plating but these accumulated rapidly in culture, mainly in microglial cells and also in neurons and astrocytes. Accumulation was very obvious after a week, as monitored by fluorescent microscopy and immunostaining for subunit c of mitochondrial ATP synthase. Photography at intervals revealed the dynamic nature of the cultures and a flow of storage bodies between cells, specifically the phagocytosis of storage-body containing cells by microglia and incorporation of the storage bodies into the host cells. No storage was observed in cultured control cells. Transduction of cell cultures with a lentiviral vector expressing a C-terminal Myc tagged CLN5 resulted in secretion of post-translationally glycosylated and processed CLN5. Transduction of CLN5-deficient cultures with this construct rapidly reversed storage body accumulation, to less than half in only six days. These results show that storage body accumulation is reversible with enzyme correction and support the use of these cultures for testing of therapeutics prior to whole animal studies.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  4′,6-diamidino-2-phenylindole; AAV; Batten disease; CIDR; CLN5; DAPI; Endo H; Endoglycosidase H; FBS; Fluorescent storage bodies; GFAP; GFP; Gene therapy; LVMNDU3; Lentiviral vector; M6P; M6PR; MAP; MOI; NCL; Neural cell culture; Neuronal ceroid lipofuscinoses; PAGE; PBS; PDI; PNGase F; PVDF; SDS; Sheep; TU; Transduction; adeno-associated virus; controlled internal drug (progesterone) release device; days in vitro; div; foetal bovine serum; glial fibrillary acidic protein; green fluorescent protein; lentiviral derived vector with a myeloid sarcoma virus U3 element; mannose-6-phosphate; mannose-6-phosphate receptor; microtubule associated protein; multiplicity of infection; neuronal ceroid lipofuscinosis; peptide-N-glycosidase F; phosphate buffered saline, pH7.2; polyacrylamide gel electrophoresis; polyvinylidene fluoride; protein disulphide isomerase; sodium dodecyl sulphate; transducing units

Mesh:

Substances:

Year:  2013        PMID: 24269732     DOI: 10.1016/j.nbd.2013.11.011

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  17 in total

1.  An EEG Investigation of Sleep Homeostasis in Healthy and CLN5 Batten Disease Affected Sheep.

Authors:  Nicholas Perentos; Amadeu Q Martins; Robin J M Cumming; Nadia L Mitchell; David N Palmer; Stephen J Sawiak; A Jennifer Morton
Journal:  J Neurosci       Date:  2016-08-03       Impact factor: 6.167

2.  Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis.

Authors:  Andrew E Arrant; Vincent C Onyilo; Daniel E Unger; Erik D Roberson
Journal:  J Neurosci       Date:  2018-01-29       Impact factor: 6.167

Review 3.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

4.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

Review 5.  A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis.

Authors:  I Basak; H E Wicky; K O McDonald; J B Xu; J E Palmer; H L Best; S Lefrancois; S Y Lee; L Schoderboeck; S M Hughes
Journal:  Cell Mol Life Sci       Date:  2021-04-01       Impact factor: 9.261

6.  Novel likely disease-causing CLN5 variants identified in Pakistani patients with neuronal ceroid lipofuscinosis.

Authors:  Beenish Azad; Stephanie Efthymiou; Tipu Sultan; Marcello Scala; Javeria Raza Alvi; Caroline Neuray; Natalia Dominik; Asma Gul; Henry Houlden
Journal:  J Neurol Sci       Date:  2020-04-07       Impact factor: 3.181

7.  Aberrant Autophagy Impacts Growth and Multicellular Development in a Dictyostelium Knockout Model of CLN5 Disease.

Authors:  Meagan D McLaren; Sabateeshan Mathavarajah; William D Kim; Shyong Q Yap; Robert J Huber
Journal:  Front Cell Dev Biol       Date:  2021-07-05

8.  Visual system pathology in a canine model of CLN5 neuronal ceroid lipofuscinosis.

Authors:  Grace Robinson Kick; Elizabeth J Meiman; Julianna C Sabol; Rebecca E H Whiting; Juri Ota-Kuroki; Leilani J Castaner; Cheryl A Jensen; Martin L Katz
Journal:  Exp Eye Res       Date:  2021-06-30       Impact factor: 3.770

9.  Australian Cattle Dogs with Neuronal Ceroid Lipofuscinosis are Homozygous for a CLN5 Nonsense Mutation Previously Identified in Border Collies.

Authors:  A Kolicheski; G S Johnson; D P O'Brien; T Mhlanga-Mutangadura; D Gilliam; J Guo; T D Anderson-Sieg; R D Schnabel; J F Taylor; A Lebowitz; B Swanson; D Hicks; Z E Niman; F A Wininger; M C Carpentier; M L Katz
Journal:  J Vet Intern Med       Date:  2016-05-20       Impact factor: 3.333

Review 10.  Cellular models of Batten disease.

Authors:  Christopher J Minnis; Christopher D Thornton; Lorna M FitzPatrick; Tristan R McKay
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-10-23       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.